Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Retreatment vs Chemotherapy in Advanced Melanoma
NCT01709162Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2013
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Mar 2013; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01709162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709162.